Display options
Share it on

Clin Transpl. 2015;31:69-78.

Hepatitis C and Human Immunodeficiency Virus Kidney Transplantation: The Mount Sinai Experience.

Clinical transplants

Vinay Nair, Rafael Khaim, Fadi El-Salem, Rebecca Kent, Susan Lerner, Amnon Berger, Leandra Miko, Brett Rollins, Zeynep Ebcioglu, Veronica Delaney, Vinita Sehgal, Madhav Menon, Scott Ames, Alan Benvenisty, Vikram Wadhera, Antonious Arvelakas, Thomas Schiano, Meena Rana, Shirish Huprikar, Sander Florman, Ron Shapiro

Affiliations

  1. Recanati/Miller Transplantation Institute, The Mount Sinai Medical Center, New York, NY.
  2. Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY.
  3. Clinical Virology Unit and Department of Biochemistry and the Chanock Center for Virology, IMRIC, Hadassah Hebrew University Medical Center and Faculty of Medicine, Jerusalem, Israel.
  4. Pharmacy Department, The Mount Sinai Medical Center, New York, NY.
  5. Department of Medicine, Infectious Disease Division, Icahn School of Medicine at Mount Sinai, New York, NY.

PMID: 28514569

Abstract

Mount Sinai Hospital in New York has a long history in the field of organ transplantation. The first kidney transplant at Mount Sinai was performed in 1967 by the late Dr. Lewis Burrows and the first laparoscopic donor nephrectomy in New York was performed at Mount Sinai in 1996. Over 3000 kidney transplantations have been performed at Mount Sinai. In the early 1990s, the first hepatitis C virus (HCV) positive patient at Mount Sinai underwent a kidney transplant and the first kidney transplant in a patient with human immunodeficiency virus (HIV) in New York was performed at Mount Sinai in 2001. In general, these patients have done well after renal transplantation, with outcomes similar to those seen in non-infected patients. This chapter will describe the evolution of immunosuppressive regimens in HCV positive and HIV positive patients, and will describe the outcomes of kidney transplantation in these patients. Given the favorable outcomes, it is reasonable to continue to offer renal transplantation as a treatment for end stage renal disease patients with HCV and/or HIV.

Copyright© 2016 by the Terasaki Foundation Laboratory.

Keywords: HCV; HIV; immunosuppression; renal; single center; transplantation

Publication Types